Quantcast
 
Read Larry Connors' blogShort Term Trading Strategies


 

Alpha Innotech Reports First Quarter 2009 Results

Tue. May 12, 2009; Posted: 10:16 PM
Stocks RSS
SAN LEANDRO, Calif., May 12, 2009 (BUSINESS WIRE) -- APNO | Quote | Chart | News | PowerRating -- Alpha Innotech Corp. (OTCBB:APNO), a leading provider of bioanalytical systems for drug discovery and life science research, today reported financial results for their first quarter ending March 31, 2009.

First quarter revenues of $3.69 million increased 1% from the $3.67 million reported in the same period in 2008.

The Company posted a net loss of $218,963 in the first quarter ending March 31, 2009 as compared to a $2,057 net loss in the comparable period of 2008.

Excluding interest, depreciation and stock-based compensation on a non-GAAP basis, the Company had net income of $203,698 for the first quarter of 2009 compared to $338,310 for the first quarter of 2008. The non-GAAP net income (loss) is reconciled to comparable GAAP net income (loss) in the table entitled "Non-GAAP Calculation of Net Income."

"Our 1% revenue increase does not reflect the fact that our new orders increased 17% in the first quarter of 2009 compared to the first quarter of 2008. By comparison, our first quarter of 2008 benefitted from a significantly larger beginning backlog as well as a one-time gain from a patent sale," said Ron Bissinger, Chief Executive Officer of Alpha Innotech.

Recent Highlights

-- Launched SpectraPlex(TM), a multicolor fluorescent Western blotting kit optimized for use on the Company's FluorChem(R) Q imager

-- Added sales personnel in China and India to continue building revenue-generating capabilities in the rapidly growing Asia region

-- Launched a portfolio of new service products allowing customers to choose from a variety of service and support options

More information on Alpha Innotech can be found at the Company's website www.alphainnotech.com.

About Alpha Innotech Corp.

With over 10,000 systems sold worldwide, Alpha Innotech is a leading developer, manufacturer and marketer of digital imaging and analysis systems for the life science research and drug discovery markets. Our goal is to combine instruments, reagents and bioinformatics software to offer integrated modular technology platforms for functional genomics, proteomics and cell analysis markets. Our customers include pharmaceutical and biotechnology companies as well as universities, medical centers, government research institutes and agencies worldwide.

Use of Non-GAAP Financial Measures

To supplement the Company's financial statements presented in accordance with GAAP, the Company is also providing non-GAAP financial information. The presentation of non-GAAP financial information should be considered in addition to the Company's GAAP results and is not intended to be considered in isolation or as a substitute for financial information prepared and presented in accordance with GAAP. The Company believes that both management and investors benefit from referring to non-GAAP financial information that excludes certain expenses in their assessment of the Company's performance. The Company also believes that investors benefit from increased transparency into supplemental information used by management in its financial and operational decision making.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, statements related to the continued expansion of our international sales channels, our continued development, manufacture and supply of new products, and the ability to control our expenses, and is subject to the safe harbor created by those sections. Words such as "will," "expect," "believe," "suggest," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations. These forward-looking statements involve a number of risks and uncertainties that include, but are not limited to, changing worldwide economic conditions, current volatility and disruption in the capital and credit markets, and the Company's ability to obtain additional financing if needed, that could cause actual results to differ materially from those anticipated or planned by these forward-looking statements. Please also refer to the risk factors described under "Risk Factors" and elsewhere in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update the forward-looking statements contained in this news release except as required by law.

Alpha Innotech Corp.
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except per share amounts)
                                               Three Months Ended
                                               March 31,
                                               2009                2008
Revenue                                        $   3,691           $   3,668
Cost of Goods Sold                                 1,688               1,557
Gross profit                                       2,003               2,111
Operating expenses:
Sales and Marketing                                1,185               1,185
Research and Development                           313                 375
General and Administrative                         584                 567
Total operating expenses                           2,082               2,127
Loss from operations                               (79        )        (16        )
Other income (expense):
Interest expense                                   (132       )        (83        )
Other income (expense), net                        (8         )        (3         )
Sale of patents                                    --                  100
Net loss applicable to common stockholders     $   (219       )    $   (2         )
Net loss per share:
Basic and Diluted                              $   (0.02      )    $   (0.00      )
Weighted average shares outstanding:
Basic and Diluted                                  10,925,224          10,536,390
Alpha Innotech Corp.
Condensed Consolidated Balance Sheets
As of March 31, 2009 and December 31, 2008
(in thousands)
                                             2009             2008
Assets
Current assets:
Cash and cash equivalents                    $    382         $    649
Restricted cash                                   100              50
Accounts receivable, net                          2,062            3,033
Inventory, net                                    1,764            1,464
Prepaid expenses and other current assets         155              155
Total current assets                              4,463            5,351
Property and equipment, net                       795              790
Loan costs, net                                   81               119
Other assets                                      105              91
Total assets                                 $    5,444       $    6,351
Liabilities and shareholders'
deficit
Current liabilities:
Accounts payable                             $    1,086       $    880
Accrued liabilities                               1,005            1,110
Current portion of debt                           2,064            2,936
Deferred revenue                                  1,173            1,217
Other liabilities                                 128              152
Total current liabilities                         5,456            6,295
Debt, net of current portion                      154              152
Total shareholders' deficit                       (166  )          (96   )
Total liabilities and shareholders' deficit  $    5,444       $    6,351
Alpha Innotech Corp.
Non-GAAP Calculation of Net Income
(Unaudited)
(in thousands)
                             Three Months Ended
                             March 31,
                             2009       2008
GAAP net loss                $   (219)  $   (2)
Interest                         132        83
Depreciation                     143        137
Stock-based compensation         148        120
Non-GAAP basis income        $   204    $   338

SOURCE: Alpha Innotech Corp.

Alpha Innotech Corp. 
Michael P. Henighan, CFO, 510-483-5610
For full details for APNO click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Most Popular News
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.